Association of Decreased Fecal Microbiota Akkermansia with Increased High-Sensitivity C-Reactive Protein Levels in Patients with Unstable Angina

Abstract

Background and Objective

Inflammation plays a pivotal role in the progression of coronary artery disease (CAD). High-sensitivity C-reactive protein (hsCRP) serves as a well-established biomarker for assessing cardiovascular inflammation risk. However, the specific intestinal microbiota alteration contributing to increased inflammation remains unclear. Therefore, the present study investigated the correlation between the intestinal microbiota and inflammation in patients with unstable angina (UA).

Methods

A cohort of 92 patients with UA was recruited for this study. The plasma hsCRP level was measured via a CardioPhase hsCRP assay, fecal samples were collected after admission, and 16S rRNA sequencing was conducted to identify the fecal microbial profile. The participants were classified into two groups according to the median hsCRP level (1.11 mg/L). The composition of the fecal microbiota was compared between patients with hsCRP ≥ 1.11 mg/L and those with hsCRP < 1.11 mg/L. Additionally, the correlations between the fecal microbiota and clinical characteristics were analyzed.

Results

A notable reduction in the relative abundance of Akkermansia was observed in patients with hsCRP ≥ 1.11 mg/L, whereas the diversity of the fecal microbiota was not significantly different between patients with hsCRP ≥ 1.11 mg/L and those with hsCRP < 1.11 mg/L. Furthermore, the abundance of Akkermansia was negatively correlated with hsCRP levels.

Conclusion

This study suggested a significant association between decreased levels of Akkermansia and inflammatory risk in patients with UA. These findings underscore the potential role of the intestinal microbiota in contributing to inflammation in UA patients. Further work is needed on the mechanism by which the microbiota contributes to inflammatory risk.

Keywords

Unstable angina / Inflammation risk / High-sensitivity C-reactive protein / Fecal microbiota / Akkermansia

References

[1] HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med., 2005, 352(16): 1685-1695.

[2] WolfD, LeyK. Immunity and Inflammation in Atherosclerosis. Circ Res., 2019, 124(2): 315-327.

[3] The Writing Committee of the Annual Report on Cardiovascular Health and Diseases in China. Interpretation of the Annual Report on Cardiovascular Health and Diseases in China 2021. Cardiol Discov. 2023;3(4):277–300.

[4] LawlerPR, BhattDL, GodoyLC, et al.. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J., 2021, 42(1): 113-131.

[5] KaasenbroodL, BoekholdtSM, van der GraafY, et al.. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation., 2016, 134(19): 1419-1429.

[6] JernbergT, HasvoldP, HenrikssonM, et al.. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J., 2015, 36(19): 1163-1170.

[7] RidkerPM, EverettBM, ThurenT, et al.. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med., 2017, 377(12): 1119-1131.

[8] TardifJC, KouzS, WatersDD, et al.. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med., 2019, 381(26): 2497-2505.

[9] NidorfSM, FioletATL, MosterdA, et al.. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med., 2020, 383(19): 1838-1847.

[10] YousufO, MohantyBD, MartinSS, et al.. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?. J Am Coll Cardiol., 2013, 62(5): 397-408.

[11] ManiP, PuriR, SchwartzGG, et al.. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA Cardiol., 2019, 4(4): 314-320.

[12] GuedeneyP, ClaessenBE, KalkmanDN, et al.. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol., 2019, 73(19): 2401-2409.

[13] RidkerPM, MacFadyenJG, GlynnRJ, et al.. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Eur Heart J., 2020, 41(31): 2952-2961.

[14] LibbyP. Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond. J Am Coll Cardiol., 2017, 70(18): 2278-2289.

[15] RidkerPM, MacFadyenJG, EverettBM, et al.. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet., 2018, 391(10118): 319-328.

[16] TilgH, ZmoraN, AdolphTE, et al.. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol., 2020, 20(1): 40-54.

[17] ColletJP, ThieleH, BarbatoE, et al.. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J., 2021, 42(14): 1289-1367.

[18] BolyenE, RideoutJR, DillonMR, et al.. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol., 2019, 37(8): 852-857.

[19] KechinA, BoyarskikhU, KelA, et al.. cutPrimers: A New Tool for Accurate Cutting of Primers from Reads of Targeted Next Generation Sequencing. J Comput Biol., 2017, 24(11): 1138-1143.

[20] CallahanBJ, McMurdiePJ, RosenMJ, et al.. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods., 2016, 13(7): 581-583.

[21] DurdenC, DongQ. RICHEST–a web server for richness estimation in biological data. Bioinformation., 2009, 3(7): 296-298.

[22] LozuponeCA, HamadyM, KelleyST, et al.. Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl Environ Microbiol., 2007, 73(5): 1576-1585.

[23] DeSantisTZ, HugenholtzP, LarsenN, et al.. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol., 2006, 72(7): 5069-5072.

[24] HusonDH, MitraS, RuscheweyhHJ, et al.. Integrative analysis of environmental sequences using MEGAN4. Genome Res., 2011, 21(9): 1552-1560.

[25] AsnicarF, WeingartG, TickleTL, et al.. Compact graphical representation of phylogenetic data and metadata with GraPhlAn. PeerJ., 2015, 3. e1029

[26] WangY, ShengHF, HeY, et al.. Comparison of the levels of bacterial diversity in freshwater, intertidal wetland, and marine sediments by using millions of illumina tags. Appl Environ Microbiol., 2012, 78(23): 8264-8271.

[27] LiuYX, QinY, ChenT, et al.. A practical guide to amplicon and metagenomic analysis of microbiome data. Protein Cell., 2021, 12(5): 315-330.

[28] CaniPD, DepommierC, DerrienM, et al.. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol., 2022, 19(10): 625-637.

[29] CreaF, LiuzzoG. Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine. Eur Heart J., 2016, 37(30): 2414-2416.

[30] LiberaleL, MontecuccoF, SchwarzL, et al.. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res., 2021, 117(2): 411-422.

[31] AhnJH, TantryUS, KangMG, et al.. Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. JACC Asia., 2022, 2(3): 323-337.

[32] KalkmanDN, AquinoM, ClaessenBE, et al.. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J., 2018, 39(46): 4101-4108.

[33] YuM, YuanYF, YangF, et al.. Residual Inflammatory Risk in Outcomes of Chinese Patients After Percutaneous Coronary Intervention. JACC Asia., 2024, 4(8): 636-638.

[34] YangF, XiaN, GuoS, et al.. Propionate Alleviates Abdominal Aortic Aneurysm by Modulating Colonic Regulatory T-Cell Expansion and Recirculation. JACC Basic Transl Sci., 2022, 7(9): 934-947.

[35] DepommierC, EverardA, DruartC, et al.. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med., 2019, 25(7): 1096-1103.

[36] Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157–4173.

[37] NakajimaA, MitomoS, YukiH, et al.. Gut Microbiota and Coronary Plaque Characteristics. J Am Heart Assoc., 2022, 1117. e026036

[38] LiuH, ChenX, HuX, et al.. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome., 2019, 7168.

[39] MaghiniDG, DvorakM, DahlenA, et al.. Quantifying bias introduced by sample collection in relative and absolute microbiome measurements. Nat Biotechnol., 2024, 42(2): 328-338.

Funding

the National Natural Science Foundation of China(82030016)

the National Natural Science Foundation of China(82200533)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology